Research Topics
| JAY B JACKSONSummaryAffiliation: Johns Hopkins University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Analysis of nevirapine resistance mutations in cloned HIV type 1 variants from HIV-infected Ugandan infants using a single-step amplification-sequencing method (AmpliSeq)William Ian Towler
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 24:1209-13. 2008..This analysis revealed numerous NVP resistance mutations not detected by population sequencing, genetically linked NVP resistance mutations, and a high degree of genetic complexity at codons that influence NVP susceptibility...
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trialJ Brooks Jackson
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Lancet 362:859-68. 2003..Safety and efficacy data are now presented for all babies followed up to 18 months of age...- Comparison of versions 1.0 AND 1.5 of the UltraSensitive AMPLICOR HIV-1 MONITOR test for subjects with low viral loadJ Brooks Jackson
Johns Hopkins Medical Institutions, Carnegie Building, Room 415, 600 North Wolfe St, Baltimore, MD 21287, USA
J Clin Microbiol 42:2774-6. 2004..0146). Median numbers of copies per milliliter were similar for 112 samples with 50 to 3,000 copies/ml with no difference in sensitivity with a 200-copy/ml cutoff... - Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmissionJ Brooks Jackson
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
AIDS 20:217-22. 2006..To correlate nevirapine presence and concentration in cord bloods of infants born to HIV-1 infected women with report of timing of dose and HIV-1 transmission at 6 weeks of age... - Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapineDana Jones
Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 21:319-24. 2005..Further studies are needed to evaluate whether selection of minority variants with one or more NVPR mutations after single-dose NVP is clinically relevant... - Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and DTamara S Flys
Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
J Acquir Immune Defic Syndr 42:610-3. 2006..Further studies are needed to evaluate the clinical significance of NVP-resistant variants in this setting... - In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapineJessica D Church
Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 25:673-7. 2009..NVP resistance was still detected in some infants 6-12 months after sdNVP exposure. In this study, in utero HIV infection was the only factor associated with detection of NVP resistance in infants 6-8 weeks after sdNVP exposure... - Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmissionTamara S Flys
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
J Infect Dis 195:711-5. 2007..Fading (lack of detection) of K103N was documented in 16 women by 2 years, 43 women by 3 years, and 55 women by 4 and 5 years. Slower fading was independently associated with HIV-1 subtype (D>A) and higher pre-NVP viral load... - HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and DJessica D Church
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 23:764-8. 2007.... - Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012Tamara Flys
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
J Infect Dis 192:24-9. 2005..Sensitive resistance assays may provide new insight into the impact of antiretroviral drug exposure on HIV-1 evolution... - Detection of K103N in Ugandan women after repeated exposure to single dose nevirapineTamara S Flys
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
AIDS 21:2077-82. 2007..Repeat use of SD NVP for pMTCT may influence emergence and persistence of NVP-resistant variants... - Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infantsJessica D Church
Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 25:657-63. 2009..LigAmp was useful for the detection and quantification of minority variants. PhenoSense HIV provided a direct and quantitative measure of NNRTI susceptibility... - Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and DJessica D Church
Department of Pathology, The Johns Hopkins Medical Institutions, Ross Bldg. 646, 720 Rutland Ave, Baltimore, MD 21205, USA
J Mol Diagn 8:430-2; quiz 527. 2006..Further studies are needed to compare the sensitivity of different assays for detection of HIV-1 drug resistance mutations and to determine the clinical relevance of HIV-1 minority variants... - Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newbornsSusan H Eshleman
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
AIDS 19:2167-9. 2005..Nevirapine resistance was more frequent in infants with subtype C than with subtypes A and D (87 versus 50%, P = 0.016)... - Analysis of HIV type 1 gp41 and enfuvirtide susceptibility among men in the United States who were HIV infected prior to availability of HIV entry inhibitorsSarah E Hudelson
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 25:701-5. 2009..However, most of the mutations were not associated with phenotypic ENF resistance... - Late postnatal transmission of HIV-1 and associated factorsTaha E Taha
Department of Epidemiology, Bloomberg School of Public Health, Baltimore, MD 21205, USA
J Infect Dis 196:10-4. 2007..The present study was undertaken to determine the risk and timing of late postnatal transmission (LPT) of human immunodeficiency virus type 1 (HIV-1)... 
Estimate of infant HIV-free survival at 6 to 8 weeks of age due to maternal antiretroviral prophylaxis in Sub-Saharan Africa, 2004-2005Caroline E Boeke
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
J Int Assoc Physicians AIDS Care (Chic) 7:133-40. 2008..The number of infections and deaths averted per year increased from 13 710 in 2004 to 17 764 in 2005. The estimated number of infant HIV infections and deaths averted in 2004 and 2005 due to prophylaxis is encouraging...- HIV-1 tropism and survival in vertically infected Ugandan infantsJessica D Church
Johns Hopkins University, Baltimore, Maryland, USA
J Infect Dis 197:1382-8. 2008..We analyzed HIV-1 coreceptor tropism in Ugandan infants enrolled in the HIVNET (HIV Network for Prevention Trials) 012 trial... - Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral Carlum Shiu
Johns Hopkins University, Baltimore, MD 21287, USA
J Virol 83:9731-42. 2009..001). These findings suggest that ongoing virus replication contributes to low-level viremia in patients on HAART and that this ongoing replication is subject to CD8(+) T-cell selective pressures... - Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVPSusan H Eshleman
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
J Infect Dis 192:30-6. 2005..Here, we evaluate the rate of NVP resistance mutations in women with subtype C... - Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012Susan H Eshleman
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
J Acquir Immune Defic Syndr 39:593-7. 2005..To compare the rate of mother-to-child transmission (MTCT) in women with subtype A versus D HIV-1 who received single-dose nevirapine (NVP)... - Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012Susan H Eshleman
The Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
J Acquir Immune Defic Syndr 40:24-9. 2005..This study examined emergence and fading of specific NVPR mutations in women with these subtypes... - Effect of periodic vitamin A supplementation on mortality and morbidity of human immunodeficiency virus-infected children in Uganda: A controlled clinical trialRichard D Semba
Department of Ophthalmology Johns Hopkins School of Medicine, Baltimore, MD, USA
Nutrition 21:25-31. 2005..We investigated whether vitamin A supplementation would decrease mortality and morbidity rates in children infected with the human immunodeficiency virus (HIV)... - Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1Susan H Eshleman
Johns Hopkins University, Baltimore, MD 21205, USA
J Infect Dis 193:479-81. 2006..20/23 [87%]; P < .001). The risk of MTCT of HIV-1 was comparable with these regimens. Infant-only prophylaxis also eliminates the development of NVP resistance in mothers... - Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutationsSusan H Eshleman
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 22:289-93. 2006..Further studies are needed to define the genetic correlates of antiretroviral drug resistance in nonsubtype B HIV-1... - Human papillomavirus prevalence and cytopathology correlation in young Ugandan women using a low-cost liquid-based Pap preparationJanis M Taube
Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Diagn Cytopathol 38:555-63. 2010..Notably, the manual low-cost liquid-based Pap preparation is practical in this setting and offers an alternate method for local studies of HPV vaccine efficacy... - Survival of Ugandan infants with subtype A and D HIV-1 infection (HIVNET 012)Susan H Eshleman
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
J Acquir Immune Defic Syndr 31:327-30. 2002..We found no association between HIV-1 subtype (A vs. D) and infant survival in this cohort. Further studies are needed to evaluate whether HIV-1 subtype influences clinical outcome in pediatric HIV-1 infection... - A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high riskJ Brooks Jackson
Departments of Pathology and Medicine, Johns Hopkins University, Baltimore, Maryland 21287, USA
AIDS 17:547-53. 2003..50).. - Analysis of HIV-1 variants by cloning DNA generated with the ViroSeq HIV-1 Genotyping SystemSusan H Eshleman
Department of Pathology, The Johns Hopkins Medical Institutions, Ross Bldg. 646, 720 Rutland Ave, Baltimore, MD 21205, USA
Biotechniques 35:614-8, 620, 622. 2003 - Identification of Ugandan HIV type 1 variants with unique patterns of recombination in pol involving subtypes A and DSusan H Eshleman
Department of Pathology, Johns Hopkins Medical Institutions, Ross Building 646, 720 Rutland Avenue, Baltimore, MD 21205, USA
AIDS Res Hum Retroviruses 18:507-11. 2002..The large number of different types of pol recombinants identified suggests that recombination occurs readily in the pol region. Perinatal transmission of the recombinant viruses demonstrates their evolutionary stability... - Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012)Susan H Eshleman
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
J Acquir Immune Defic Syndr 35:126-30. 2004..To compare the number and type of nevirapine (NVP) resistance mutations detected in Ugandan women with subtype A vs. D HIV-1 infection after single-dose NVP prophylaxis... - Pregnancy does not affect HIV incidence test results obtained using the BED capture enzyme immunoassay or an antibody avidity assayOliver Laeyendecker
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
PLoS ONE 5:e13259. 2010..Accurate incidence estimates are needed for surveillance of the HIV epidemic. HIV surveillance occurs at maternal-child health clinics, but it is not known if pregnancy affects HIV incidence testing... - Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infectionCraig W Hendrix
Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
J Acquir Immune Defic Syndr 37:1253-62. 2004..Overall, however, the average change in viral load across all patients was +0.03 log10 HIV RNA. Given these results, AMD3100 is not being further developed for ARV therapy, but development continues for stem cell mobilization... - Nevirapine resistance after single dose prophylaxisSusan H Eshleman
Department of Pathology, Johns Hopkins Medical Institutions, Ross Bldg 646, 720 Rutland Ave, Baltimore, MD 21205, USA
AIDS Rev 4:59-63. 2002..We review studies examining the emergence and fading of NVP-resistant HIV-1 in women and infants who received single dose NVP prophylaxis, and discuss the potential clinical relevance of NVP-resistance in this setting... - Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in UgandaLaura A Guay
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
AIDS 16:1391-400. 2002..Data suggest that a 400 mg/kg dose of HIVIGLOB would be the most appropriate dose for a subsequent efficacy trial of HIVIGLOB for the prevention of mother to child HIV transmission... - Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmissionJessica D Church
School of Medicine, Johns Hopkins University, Baltimore, Maryland 21205, USA
J Infect Dis 198:1075-82. 2008..We analyzed NVP resistance in HIV-infected Ugandan infants who received either SD NVP or extended NVP prophylaxis... - Iron deficiency anemia is highly prevalent among human immunodeficiency virus-infected and uninfected infants in UgandaDana Totin
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
J Nutr 132:423-9. 2002..049). Infants in Uganda have an extremely high prevalence of anemia, and nearly half of the anemia is due to iron deficiency. The erythropoietin response to anemia appears to be upregulated among infants with iron deficiency... - A modified ultrasensitive assay to detect quantified HIV-1 RNA of fewer than 50 copies per milliliterEstelle M Piwowar-Manning
Department of Pathology, Johns Hopkins Medical Institutions, 600 N Wolfe St, Carnegie Bldg, Room 415, Baltimore, MD 21287, USA
Am J Clin Pathol 120:268-70. 2003..5. None of the assays detected HIV-1 RNA in HIV-1 antibody-negative samples. The modified version 1.5 of the RNA assay is more sensitive for detecting HIV-1 RNA in significantly more patients than are versions 1.0 and 1.5... - Comparison of results obtained with Amplicor HIV-1 DNA PCR test version 1.5 using 100 versus 500 microliters of whole bloodEstelle Piwowar-Manning
Department of Pathology, 600 North Wolfe St, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
J Clin Microbiol 46:1104-5. 2008..A comparison was performed using 100 and 500 microl of whole blood from infants less than 18 months of age. The concordance rate for HIV DNA PCR-negative and -positive samples was 100% for the two different volumes... - Antenatal vitamin A supplementation increases birth weight and decreases anemia among infants born to human immunodeficiency virus-infected women in MalawiNewton Kumwenda
Department of Epidemiology and Ophthalmology, Johns Hopkins University School of Hygiene and Public Health and School of Medicine, Baltimore, MD, USA
Clin Infect Dis 35:618-24. 2002..6% and 27.8% (P=.76) and 27.7% and 32.8% (P=.21). Receipt of vitamin A improved birth weight and neonatal growth and reduced anemia, but it did not affect perinatal HIV transmission... - Analysis of HIV diversity using a high-resolution melting assayWilliam I Towler
Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 26:913-8. 2010..111). The HRM assay provides a novel, rapid method for assessing HIV diversity without sequencing. This assay could be applied to any region of the HIV genome or to other genetic systems that exhibit DNA diversity... - Analysis of length variation in the V1-V2 region of env in nonsubtype B HIV type 1 from UgandaAlexandra M Klevytska
Department of Pathology, Johns Hopkins Medical Institutions, Ross Building 646, 720 Rutland Avenue, Baltimore, MD 21205, USA
AIDS Res Hum Retroviruses 18:791-6. 2002..This assay may be helpful for studies examining the impact of env length diversity on HIV-1 transmission and pathogenesis in regions where these subtypes are prevalent... - Cross-clade T lymphocyte-mediated immunity to HIV type 1: implications for vaccine design and immunodetection assaysSheila M Keating
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 18:1067-79. 2002.... - The costs associated with adverse event procedures for an international HIV clinical trial determined by activity-based costingVictoria B Chou
Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
J Acquir Immune Defic Syndr 46:426-32. 2007..To determine costs for adverse event (AE) procedures for a large HIV perinatal trial by analyzing actual resource consumption using activity-based costing (ABC) in an international research setting... - CMV antibody prevalence and seroincidence in plateletpheresis donorsCaroline E Boeke
Department of Pathology, Johns Hopkins University, Baltimore, Maryland 21287, USA
J Clin Apher 23:63-5. 2008..To determine the prevalence and seroincidence of CMV seropositivity in plateletpheresis donors of different ages and gender... - Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trialsAbubaker Bedri
Lancet 372:300-13. 2008..FUNDING: US National Institutes of Health; US National Institute of Allergy and Infectious Diseases; Fogarty International Center... - Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1Paul Krogstad
University of California, Los Angeles School of Medicine, Departments of Pediatrics and Molecular and Medical Pharmacology, Los Angeles, CA, 90095, USA
Clin Infect Dis 34:991-1001. 2002..These regimens were similar in their drug activity, but the 4-drug regimen offered slightly more durable suppression of viremia... - Total lymphocyte count: not a surrogate marker for risk of death in HIV-infected Ugandan childrenPhilippa M Musoke
Department of Paediatrics and Child Health, Makerere University, Kampala, Uganda
J Acquir Immune Defic Syndr 49:171-8. 2008..To determine the utility of total lymphocyte count (TLC) in predicting the 12-month mortality in HIV-infected Ugandan children and to correlate TLC and CD4 cell %... - Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliterLisa M Demeter
University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
J Clin Microbiol 40:2089-94. 2002..The delay in the time required for HIV cultures to turn positive should be considered when attempting to obtain an HIV isolate from patients with suppression of plasma viral load... - Mother-to-child transmission in the United States of subtypes D and A/G human immunodeficiency virus type 1Paul Krogstad
Department of Pediatrics, University of California Los Angeles School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
AIDS Res Hum Retroviruses 18:413-7. 2002..Non-B subtypes should be considered in the management of HIV-1-infected pregnant women and children to optimize strategies to prevent and treat pediatric HIV-1 infection... - Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNAJanet Vargo
Gen Probe Incorporated, San Diego, California 92121, USA
Transfusion 42:876-85. 2002..Donor plasma samples reactive in the Procleix HIV-1/HCV assay are tested with the HIV-1 and HCV discriminatory assays to resolve whether HIV-1 RNA, HCV RNA, or both are present... - Analysis of insertions and deletions in the gag p6 region of diverse HIV type 1 strainsNatalia Marlowe
Celera Diagnostics, Alameda, California 94502, USA
AIDS Res Hum Retroviruses 20:1119-25. 2004..Further studies are needed to determine whether such genotypic differences influence viral replication capacity, antiretroviral drug susceptibility, or other phenotypic properties of these strains... - Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysisAnna Coutsoudis
J Infect Dis 189:2154-66. 2004..Biological and cultural mechanisms underlying the association between sex and late postnatal transmission should be further investigated. Interventions to decrease transmission of HIV-1 through breast-feeding are urgently needed... - Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infectionJeffrey M Jacobson
Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, New York, New York 10003, USA
J Infect Dis 188:1804-14. 2003..Studies have reported that plasma human immunodeficiency virus type 1 (HIV-1) RNA levels and CD4+ lymphocyte counts in HIV-infected patients improved after treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF)... - Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stabilityDon Brambilla
New England Research Center, Waltham, Massachusetts, USA
J Clin Microbiol 41:1888-93. 2003..Dried blood and dried plasma spots can be used as an easy and inexpensive means for the collection and storage of specimens under field conditions for the diagnosis of HIV infection and the monitoring of antiretroviral therapy... - Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and DSusan H Eshleman
J Acquir Immune Defic Syndr 42:518-21. 2006 - HIV incidence, retention rate, and baseline predictors of HIV incidence and retention in a prospective cohort study of injection drug users in Xinjiang, ChinaYuanzhi Zhang
Xinjiang Center for Disease Control and Prevention, Urumqi, China
Int J Infect Dis 11:318-23. 2007..To determine HIV seroincidence, study participant retention rate, and baseline predictors of HIV incidence and study retention among high-risk injection drug users (IDUs) in Xinjiang, China... - HIV incidence, retention, and changes of high-risk behaviors among rural injection drug users in Guangxi, ChinaLiu Wei
Guangxi Centers for Disease Control and Prevention, Nanning, China
Subst Abus 27:53-61. 2006..CONCLUSIONS: HIV incidence is high among IDU in Guangxi, China despite a self-reported decrease in some high risk behaviors over the course of the study... - Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populationsWei Huang
Monogram Biosciences, 345 Oyster Point Blvd, South San Francisco, CA 94080, USA
J Virol 81:7885-93. 2007.... - Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1Tim R Cressey
Harvard School of Public Health, Boston, MA, USA
J Acquir Immune Defic Syndr 38:283-8. 2005..To determine nevirapine (NVP) plasma levels during the postpartum period after a single intrapartum NVP dose for the prevention of mother-to-child transmission... - HIV prevalence among injection drug users in rural Guangxi ChinaWei Liu
Guangxi Centers for Disease Control and Prevention, Nanning, China
Addiction 101:1493-8. 2006..62; 95% CI 1.08, 2.43). CONCLUSIONS: HIV infection among IDU in Guangxi, one of China's major HIV epidemic regions, is high and the infection occurs predominantly among older IDU males who share rinse water...
Research Grants
- HPTN - CENTRAL LABORATORYJAY JACKSON; Fiscal Year: 2005..To optimize the amount of scientific expertise and lab capabilities needed, the HPTN CL will be based on a hub and spoke concept involving JHU, University of Pittsburgh, and the California Public Health Dept (VRDL). ..
- JHU-MCAIDS HPTN TRIAL SITE-CHINAJAY JACKSON; Fiscal Year: 2006..However, the JHU-NCAIDS collaboration does have expertise in the areas of vaccines and behavioral interventions and could potentially employ these interventions in IDUs or expand to other populations as the epidemic grows. ..
- HIV-IG FOR PREVENTION OF VERTICAL TRANSMISSIONJAY JACKSON; Fiscal Year: 2003..2. Evaluate the differences in clinical progression to AIDS, the decline in CD4 counts, and survival at 2.5 years in the HIV-1 infected infants who received HIVIG or IVIG. ..
- Johns Hopkins University-Guangxi, China Clinical Trials UnitJAY JACKSON; Fiscal Year: 2007..JHU will be the primary applicant organization which will subcontract with the Guangxi CDC those costs to conduct clinical trials at the clinical research sites. ADMINISTRATIVE COMPONENT: ..
- International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupJ Jackson; Fiscal Year: 2007....